Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in Japan
Diagnosing sarcopenia is challenging. This multicenter cross-sectional study aimed to evaluate the utility of the SARC-F score system for identifying sarcopenia in patients with chronic liver disease (CLD). We enrolled 717 patients from five participating centers who completed the SARC-F between Nov...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/15/3448 |
| _version_ | 1797525373887447040 |
|---|---|
| author | Tatsunori Hanai Atsushi Hiraoka Makoto Shiraki Ryosuke Sugimoto Nobuhito Taniki Akira Hiramatsu Nobuhiro Nakamoto Motoh Iwasa Kazuaki Chayama Masahito Shimizu |
| author_facet | Tatsunori Hanai Atsushi Hiraoka Makoto Shiraki Ryosuke Sugimoto Nobuhito Taniki Akira Hiramatsu Nobuhiro Nakamoto Motoh Iwasa Kazuaki Chayama Masahito Shimizu |
| author_sort | Tatsunori Hanai |
| collection | DOAJ |
| description | Diagnosing sarcopenia is challenging. This multicenter cross-sectional study aimed to evaluate the utility of the SARC-F score system for identifying sarcopenia in patients with chronic liver disease (CLD). We enrolled 717 patients from five participating centers who completed the SARC-F between November 2019 and March 2021. Sarcopenia was diagnosed based on the Japan Society of Hepatology Working Group on Sarcopenia in Liver Disease Consensus. Muscle strength was estimated using a grip dynamometer, and muscle mass was assessed using computed tomography or bioelectrical impedance analysis. The association between SARC-F and sarcopenia was analyzed using a logistic regression model. The optimal SARC-F cutoff value for identifying sarcopenia was determined using receiver operating characteristic (ROC) curve analysis. Of the 676 eligible patients, 15% were diagnosed with sarcopenia. The SARC-F distribution was 0 points in 63% of patients, 1 point in 17%, 2 points in 7%, 3 points in 4%, and ≥4 points in 8%. The SARC-F items of “Strength” (odds ratio (OR), 1.98; 95% confidence interval (CI), 1.03–3.80) and “Falls” (OR, 2.44; 95% CI, 1.48–4.03) were significantly associated with sarcopenia. The SARC-F value of 1 point showed a higher discriminative ability for identifying sarcopenia than the 4 points that are conventionally used (<i>p</i> < 0.001), with an area under the ROC curve of 0.68, sensitivity of 0.65, specificity of 0.68, positive predictive value of 0.27, and negative predictive value of 0.92. SARC-F is useful for identifying patients with CLD who are at risk of sarcopenia. |
| first_indexed | 2024-03-10T09:12:52Z |
| format | Article |
| id | doaj.art-4b705373d5664fd0b3889b3649368671 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T09:12:52Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-4b705373d5664fd0b3889b36493686712023-11-22T05:51:03ZengMDPI AGJournal of Clinical Medicine2077-03832021-08-011015344810.3390/jcm10153448Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in JapanTatsunori Hanai0Atsushi Hiraoka1Makoto Shiraki2Ryosuke Sugimoto3Nobuhito Taniki4Akira Hiramatsu5Nobuhiro Nakamoto6Motoh Iwasa7Kazuaki Chayama8Masahito Shimizu9Department of Gastroenterology/Internal Medicine, Gifu University Graduate School of Medicine, Gifu 501-1194, JapanGastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama 790-0024, JapanDepartment of Gastroenterology/Internal Medicine, Gifu University Graduate School of Medicine, Gifu 501-1194, JapanDepartment of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Tsu 514-8507, JapanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, JapanDepartment of Gastroenterology and Metabolism, Applied Life Science, Institute of Biomedical and Health Science, Hiroshima University, Hiroshima 734-8553, JapanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, JapanDepartment of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Tsu 514-8507, JapanCollaborative Research Laboratory of Medical Innovation, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, JapanDepartment of Gastroenterology/Internal Medicine, Gifu University Graduate School of Medicine, Gifu 501-1194, JapanDiagnosing sarcopenia is challenging. This multicenter cross-sectional study aimed to evaluate the utility of the SARC-F score system for identifying sarcopenia in patients with chronic liver disease (CLD). We enrolled 717 patients from five participating centers who completed the SARC-F between November 2019 and March 2021. Sarcopenia was diagnosed based on the Japan Society of Hepatology Working Group on Sarcopenia in Liver Disease Consensus. Muscle strength was estimated using a grip dynamometer, and muscle mass was assessed using computed tomography or bioelectrical impedance analysis. The association between SARC-F and sarcopenia was analyzed using a logistic regression model. The optimal SARC-F cutoff value for identifying sarcopenia was determined using receiver operating characteristic (ROC) curve analysis. Of the 676 eligible patients, 15% were diagnosed with sarcopenia. The SARC-F distribution was 0 points in 63% of patients, 1 point in 17%, 2 points in 7%, 3 points in 4%, and ≥4 points in 8%. The SARC-F items of “Strength” (odds ratio (OR), 1.98; 95% confidence interval (CI), 1.03–3.80) and “Falls” (OR, 2.44; 95% CI, 1.48–4.03) were significantly associated with sarcopenia. The SARC-F value of 1 point showed a higher discriminative ability for identifying sarcopenia than the 4 points that are conventionally used (<i>p</i> < 0.001), with an area under the ROC curve of 0.68, sensitivity of 0.65, specificity of 0.68, positive predictive value of 0.27, and negative predictive value of 0.92. SARC-F is useful for identifying patients with CLD who are at risk of sarcopenia.https://www.mdpi.com/2077-0383/10/15/3448muscle strengthmuscle massSARC-Fsarcopeniascreening |
| spellingShingle | Tatsunori Hanai Atsushi Hiraoka Makoto Shiraki Ryosuke Sugimoto Nobuhito Taniki Akira Hiramatsu Nobuhiro Nakamoto Motoh Iwasa Kazuaki Chayama Masahito Shimizu Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in Japan Journal of Clinical Medicine muscle strength muscle mass SARC-F sarcopenia screening |
| title | Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in Japan |
| title_full | Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in Japan |
| title_fullStr | Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in Japan |
| title_full_unstemmed | Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in Japan |
| title_short | Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in Japan |
| title_sort | utility of the sarc f questionnaire for sarcopenia screening in patients with chronic liver disease a multicenter cross sectional study in japan |
| topic | muscle strength muscle mass SARC-F sarcopenia screening |
| url | https://www.mdpi.com/2077-0383/10/15/3448 |
| work_keys_str_mv | AT tatsunorihanai utilityofthesarcfquestionnaireforsarcopeniascreeninginpatientswithchronicliverdiseaseamulticentercrosssectionalstudyinjapan AT atsushihiraoka utilityofthesarcfquestionnaireforsarcopeniascreeninginpatientswithchronicliverdiseaseamulticentercrosssectionalstudyinjapan AT makotoshiraki utilityofthesarcfquestionnaireforsarcopeniascreeninginpatientswithchronicliverdiseaseamulticentercrosssectionalstudyinjapan AT ryosukesugimoto utilityofthesarcfquestionnaireforsarcopeniascreeninginpatientswithchronicliverdiseaseamulticentercrosssectionalstudyinjapan AT nobuhitotaniki utilityofthesarcfquestionnaireforsarcopeniascreeninginpatientswithchronicliverdiseaseamulticentercrosssectionalstudyinjapan AT akirahiramatsu utilityofthesarcfquestionnaireforsarcopeniascreeninginpatientswithchronicliverdiseaseamulticentercrosssectionalstudyinjapan AT nobuhironakamoto utilityofthesarcfquestionnaireforsarcopeniascreeninginpatientswithchronicliverdiseaseamulticentercrosssectionalstudyinjapan AT motohiwasa utilityofthesarcfquestionnaireforsarcopeniascreeninginpatientswithchronicliverdiseaseamulticentercrosssectionalstudyinjapan AT kazuakichayama utilityofthesarcfquestionnaireforsarcopeniascreeninginpatientswithchronicliverdiseaseamulticentercrosssectionalstudyinjapan AT masahitoshimizu utilityofthesarcfquestionnaireforsarcopeniascreeninginpatientswithchronicliverdiseaseamulticentercrosssectionalstudyinjapan |